The Trend in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Continues to Point Skyward

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) price closed lower on Tuesday, Dec 22, sinking -8.55% below its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

A look at the daily price movement shows that the previous day close read $8.3, with intraday deals fluctuating between $6.83 and $7.93. The company’s 5Y monthly beta was ticking 3.02 while its P/E ratio in the trailing 12-month period read 0. Taking into account the 52-week price action we note that the stock hit a 52-week high of $8.99 and 52-week low of $1.58. The stock added 75.29% on its value in the past month.

BioCryst Pharmaceuticals, Inc., which has a market valuation of $1.28 Billion as of writing, is expected to release its quarterly earnings report on Mar 03, 2021- Mar 08, 2021. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Analysts tracking BCRX have forecast the quarterly EPS to grow by -$0.23 per share this quarter, while the same analysts predict the annual EPS to hit -$0.98 for the year 2020 and up to -$0.95 for 2021. In this case, analysts estimate an annual EPS growth of 0.04% for the year and -0.03% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $19.57 Million, with the likely lows of $3.2 Million and highs of $31Million. The average estimate suggests sales growth for the quarter will likely fall by -50.7% when compared to those recorded in the quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $32.08 Million for the company’s annual revenue in 2020. Per this projection, the revenue is forecast to drop -34.3% below that which the company brought in 2019.

On the technical perspective front, indicators give BCRX a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 10 analysts have assigned BCRX a recommendation rating as follows: 2 rate it as a Hold; 8 advise Buy while none analyst(s) assign an Outperform rating. None analyst(s) have tagged the BioCryst Pharmaceuticals, Inc. (BCRX) stock as Underperform, with none recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 0. The overview shows that BCRX’s price is at present 13.86% off the SMA20 and 50.17% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 61.92, with weekly volatility standing at 7.99%. The indicator jumps to 8.46% when calculated based on the past 30 days. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s beta value is holding at 3.02, while the average true range (ATR) indicator is presently reading 0.6. Considering analysts have assigned the stock a price target range of $7-$16 as the low and high respectively, we find the trailing 12-month average consensus price target to be $11.22. Based on this estimate, we see that current price is roughly -7.77% off the estimated low and 110.8% off the forecast high. Investors will no doubt be excited should the share price rise to $10, which is the median consensus price, and at which level BCRX would be +31.75% from current price.

Turning out attention to how the BioCryst Pharmaceuticals, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: BCRX’s stock is -8.55% on the day and +147.23% in the past 12 months, while Zoetis Inc Cl A (ZTS) is trading +0.62% in the latest session and is positioned +22.26% up on its price 12 months ago. Another comparison is with Takeda Pharmaceutical CO Ltd (TAK) whose stock price is down -0.75% in the current trading session, but has tanked -7.79% over the past year. Also, Catalent Inc (CTLT) currently showed downtrend of -8.55% while its price kept floating at 147.23% over the past year. As for BioCryst Pharmaceuticals, Inc., the P/E ratio stands at 0 lower than that of Zoetis Inc Cl A’s at 46.46 and Takeda Pharmaceutical CO Ltd’s 22.75. Elsewhere in the market, the S&P 500 Index has fell -0.21% in today’s early trading, with the Dow Jones Industrial also seeing a negative session so far with -0.67%.

An analysis of the BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock in terms of its daily trading volume indicates that the 3-month average is 6.51 Million. However, this figure increases on the past 10-day timeline to an average of 9.04 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Latest records show that the company has 176.57 Million in outstanding shares. According to data from Thomson Reuters, insiders’ percentage holdings are 0.85% of outstanding shares while the percentage share held by institutions stands at 74.59%. The stats also highlight that short interest as of November 29, 2020, stood at 37.42 Million shares, which puts the short ratio at the time at 7.84. From this we can glean that short interest is 21.19% of company’s current outstanding shares. Notably, we see that shares short in November fell slightly given the previous month’s figure stood at 41.32 Million. But the +120% upside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.

The small cap to buy before 2021

There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune!

Get all the details here >>


Latest posts